Blockchain Registration Transaction Record

Tonix Pharma's Lyme Disease Antibody Shows 4-Month Protection in Phase 1 Trial

Tonix Pharmaceuticals announces positive Phase 1 data for TNX-4800, a long-acting monoclonal antibody for Lyme disease prevention showing 4-month protection in healthy subjects.

This news matters because Lyme disease is a rapidly growing public health threat, with approximately 476,000 cases diagnosed annually in the U.S. alone according to CDC estimates. Current prevention relies heavily on personal protective measures and prompt antibiotic treatment after tick bites, which often fails when infections go undetected. A long-acting preventative antibody like TNX-4800 could revolutionize Lyme disease management by providing months of protection with a single injection, particularly benefiting outdoor workers, residents of endemic areas, and those with frequent exposure to tick habitats. For the millions at risk, this represents potential liberation from the constant worry of contracting a disease that can cause debilitating neurological, cardiac, and joint problems if untreated. Successful development could also reduce healthcare costs associated with chronic Lyme disease complications and decrease antibiotic overuse for prophylaxis.